San Diego, CA – February 6, 2014 — Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, announced today that Dr. Henry Ji, President and Chief Executive Officer of Sorrento, will present at the 16th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 16th Annual BIO CEO & Investor Conference will take place February 10 -11 at the Waldorf Astoria in New York City.
Event: 16th Annual BIO CEO & Investor Conference
When: Monday, February 10, 2014 at 4:30 PM EST
Where: Duke of Windsor (4th Floor) – Waldorf Astoria
A live webcast of the presentation can be accessed through the investor relations section of the Company’s website at www.sorrentotherapeutics.com. Following the live presentation, a replay of the webcast will be available on the Company’s website for 30 days.
About Sorrento
Sorrento is an oncology company developing new treatments for cancer and associated pain. Sorrento’s most advanced asset Cynviloq, the next-generation paclitaxel, will commence its registrational trial and be developed under the abbreviated 505(b)(2) regulatory pathway. Sorrento is also developing RTX, a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the National Institutes of Health to treat terminal cancer patients suffering from intractable pain. The Company has made significant advances in developing human monoclonal antibodies, complemented by a comprehensive and fully integrated Antibody Drug Conjugate (ADC) platform that includes proprietary conjugation chemistries, linkers, and toxic payloads. Sorrento’s strategy is to enable a multi-pronged approach to combating cancer with small molecules, therapeutic antibodies, and ADCs.
Forward-Looking Statements
This press release contains forward-looking statements under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the potential for products to be successfully developed using proprietary technologies; the synergies and prospects for a combined enterprise going forward, including the retention of key personnel; and the clinical development and commercial potential of conjugated antibodies that may be developed based on recently acquired technologies; the potential for claims from third parties regarding the use of the ADCs and related technology that may be developed; the costs and expenses associated with additional clinical development programs from successful product development efforts, if any; and other matters that are described in Sorrento’s Annual Report on Form 10-K for the year ended December 31, 2012, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.
Contact(s):
Mr. Amar Singh
EVP and Chief Business Officer
Sorrento Therapeutics, Inc.
asingh@sorrentotherapeutics.com
T: + 1 (858) 210-3719
Ian Stone
Account Director
Canale Communications
ian@canalecomm.com
T: + 1 (619) 849-5388
